Five Under 5: Top Oncology Videos for the Week of 8/3

Welcome to The Five Under 5, your go-to roundup of the top 5 videos of the week.

These short videos are designed for busy oncologists to view on the go, and feature expert insights on breaking news, regulatory updates, practice-changing data shared at medical meetings, and other key topics in the realm of oncology.

Here’s what you may have missed:

Role of Casdatifan Plus Cabozantinib in Clear Cell RCC: Rana R. McKay, MD

Rana R. McKay, MD, FASCO, from UC San Diego Health, highlighted the promising results of combining casdatifan with cabozantinib (Cabometyx) for second-line treatment in clear cell renal cell carcinoma (ccRCC). Presented at the 2025 ASCO Annual Meeting, data from the phase 1 ARC-20 study (NCT05536141) showed a 46% overall response rate (ORR) with this combination in patients previously treated with anti–PD-1/PD-L1 therapies. She noted that this is a notable improvement over the 25% to 30% response typically seen with single-agent cabozantinib in historical data. McKay explained that casdatifan targets the HIF-2α pathway central to RCC, and cabozantinib’s multikinase inhibition complements this mechanism, potentially driving the enhanced efficacy. Safety data showed common treatment-related adverse effects, including anemia, fatigue, elevated liver enzymes, and diarrhea. Based on these findings, the combination’s synergistic potential will be further evaluated in an upcoming phase 3 trial.

FDA Approval of Dordaviprone for Diffuse Midline Glioma: Timothy Cloughesy, MD

Timothy F. Cloughesy, MD, of UCLA Health Jonsson Comprehensive Cancer Center, discussed the FDA’s accelerated approval of dordaviprone (Modeyso) for patients with H3K27M-mutant diffuse midline glioma who have progressed after prior therapy. This approval was based on pooled data from multiple phase 1 and 2 trials, including ONC006 (NCT02525692), ONC013 (NCT03295396), ONC014 (NCT03416530), ONC018 (NCT03134131), and expanded-access ONC016 (NCT05392374). Cloughesy emphasized that objective tumor shrinkage in these single-arm studies is a key indicator of drug activity, as these tumors typically do not regress spontaneously. He noted the importance of differentiating true drug response from stable disease based on tumor growth prior to treatment, highlighting that meaningful tumor regression was observed with dordaviprone.

Evolutions in Clinical Trial Design in the RCC Treatment Paradigm: Naomi B. Haas, MD

Naomi B. Haas, MD, of the Hospital of the University of Pennsylvania and Abramson Cancer Center, discussed the phase 3 KEYNOTE-564 trial (NCT03142334) evaluating adjuvant pembrolizumab (Keytruda) for 1 year vs placebo in patients with ccRCC. She explained that recent adjuvant trials with immune checkpoint inhibitors such as pembrolizumab focus on higher-risk populations, differing from earlier VEGF TKI studies. Haas highlighted differences in trial designs, including treatment duration and patient selection, noting that KEYNOTE-564 enrolled 994 patients and used investigator-assessed disease-free survival as its primary end point. The trial also assessed overall survival and safety as key secondary end points.

JNJ-5322 in Relapsed/Refractory Multiple Myeloma: Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD

Rakesh Popat, MBBS, MRCP, FRCPath, PhD, of University College London Hospitals and the National Institute for Health Research University College London Hospitals Clinical Research Facility, discussed efficacy results from a phase 1 study (NCT05652335) of the trispecific antibody JNJ-5322 in relapsed/refractory multiple myeloma. He reported that all patients in the BCMA/GRPC5D–naive cohort treated at the recommended phase 2 dose (RP2D) of 100 mg every 4 weeks achieved an ORR of 100%, with a very good partial response rate over 90%. In contrast, the BCMA/GRPC5D–exposed subgroup experienced an ORR of 55%, with a complete response or better rate of 30%. Popat noted that no disease progression was observed in the BCMA/GRPC5D–naive cohort at the RP2D, with a 12-month progression-free survival rate of 95%.

Next Steps for Investigating Relacorilant in Platinum-Resistant Ovarian Cancer: Alexander B. Olawaiye, MD

Alexander B. Olawaiye, MD, of the University of Pittsburgh and Magee-Women’s Hospital, discussed future research plans with relacorilant combined with nab-paclitaxel (Abraxane) in platinum-resistant ovarian cancer. He highlighted interim results from the phase 3 ROSELLA trial (NCT05257408), showing improved overall survival with the combination vs nab-paclitaxel alone. Olawaiye noted ongoing subgroup and secondary analyses aimed at identifying patients who benefit most from the regimen. He also mentioned the initiation of the phase 2 BELLA trial (NCT06906341), evaluating relacorilant, nab-paclitaxel, and bevacizumab (Avastin) in a broader advanced ovarian cancer population.